Oncology Based in-Vivo CRO Market Report 2025

The oncology based in-vivo cro market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to increasing focus on oncology therapeutics, increasing incidence of cancer, shift towards personalized medicine, pharmaceutical industry growth, and demand for target-specific therapies.

The oncology based in-vivo cro market size is expected to see rapid growth in the next few years. It will grow to $2.28 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to emerging market opportunities, a shift towards immuno-oncology therapies, a rise in oncology clinical trials, precision medicine, and targeted therapies. Major trends in the forecast period include regenerative medicine and cell therapies, demand for faster drug development, digitalization and data analytics, focus on tumor microenvironment, and rise in biologics and immunotherapies.

The increasing incidence of cancer is projected to drive growth in the oncology-based in-vivo contract research organization (CRO) market in the future. Cancer is characterized by a group of diseases where abnormal cells divide uncontrollably, invade surrounding tissues, and can spread to other parts of the body via the blood and lymphatic systems. Effective cancer diagnosis and treatment necessitate innovative drugs and devices that undergo various preclinical trials, clinical trials, and regulatory processes before they can reach the market. An oncology in-vivo CRO is a company contracted by a sponsor to provide research services, including conducting all or part of the steps involved in preclinical in-vivo studies (testing on living organisms such as animals, plants, or whole cells) prior to human trials. As the prevalence of cancer continues to rise, the demand for innovative treatments and therapies is also increasing, thereby propelling the growth of the oncology-based in-vivo CRO market. For example, the American Cancer Society, a non-profit organization based in the U.S., reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases identified in the country in 2022. In 2024, an estimated 620,000 cancer deaths are anticipated, reflecting a slight increase in mortality rates. Consequently, the rising prevalence of cancer is driving growth in the oncology-based in-vivo CRO market.

The upsurge in healthcare spending is expected to drive the expansion of the oncology-based in-vitro CRO market. Healthcare expenditure, encompassing costs related to healthcare services, significantly influences the development and accessibility of in-vitro CRO services within the oncology sector. Notably, the Canadian Institute for Health Information reported a rise in healthcare expenditure to $331 billion in 2022, indicating an 0.8% increase from the previous year. This surge in spending accentuates the market's growth within the oncology-based in-vitro CRO domain.

Leading companies in the oncology-based in-vivo CRO market are increasingly focusing on personalized oncology models to establish a competitive edge. These personalized oncology models leverage patient-derived xenografts (PDXs) to develop customized treatment strategies, thereby improving the relevance and effectiveness of preclinical studies. For example, in 2022, Charles River Laboratories, a life sciences company based in the U.S., introduced its OncoMouse platform, which utilizes PDX technology for more precise tumor modeling. This platform offers high-throughput screening capabilities and real-time monitoring of tumor growth, facilitating quick evaluations of therapeutic responses. Furthermore, it includes integrated data analytics to refine treatment protocols according to individual patient profiles. These developments represent a significant shift toward more effective and patient-focused methods in cancer research.

Companies within this market segment are focusing on novel solutions such as CAR T-cell therapies to gain a competitive edge. For instance, Seattle Children's Hospital and Research Institute launched BrainChild Bio in May 2023, targeting CAR T-cell therapies for pediatric brain tumors such as diffuse intrinsic pontine gliomas (DIPG). This platform incorporates synthetic technologies to enhance CAR T-cell therapy for CNS malignancies, aiming to expand its applications to other challenging brain tumors such as glioblastoma and brain metastases. The pursuit of these innovative therapies signifies a strategic move to advance treatment options within the oncology-based in-vivo CRO market.

In March 2023, ClinChoice Medical Development, a US-based contract research organization (CRO) that provides research services to accelerate drug and device approvals, acquired Cromsource S.r.l. for an undisclosed amount. Through this acquisition, ClinChoice Medical Development expands its operational capabilities with additional delivery hubs to complement its existing network in Europe and the US. Data science technology offerings in several areas, including risk-based monitoring and decentralized clinical trials, are expanded through acquisition. Cromsource S.r.l. is an Italy-based contract research organization that provides full-research services to the pharmaceutical, biotechnology, and medical device industries.

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

North America was the largest region in the oncology based in-vivo CRO market in 2024. North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology based in-vivo cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An oncology-focused in-vivo contract research organization (CRO) is a company contracted by another entity to conduct various stages of preclinical in-vivo studies for oncology drugs or devices. This includes designing, overseeing, monitoring, and analyzing preclinical in-vivo research involving living organisms such as animals, plants, or cells.

The primary areas of focus for oncology-based in-vivo CROs encompass blood cancer, solid tumors, and other related indications. Blood cancers originate from tissues responsible for blood formation, such as immune cells and bone marrow, including leukemia, lymphoma, and multiple myeloma. These CROs provide in-vivo testing services utilizing models such as blood cancer-based xenografts and others to expedite drug development research, aiding sponsors of drugs and devices in gaining market approval. Various models, including syngeneic, xenograft, patient-derived xenograft (PDX), and others, are employed by oncology-based in-vivo CROs and applied within hospital and rehabilitation settings.

The oncology based in-vivo CRO software market research report is one of a series of new reports that provides oncology based in-vivo CRO software market statistics, including oncology based in-vivo CRO software industry global market size, regional shares, competitors with a oncology based in-vivo CRO software market share, detailed oncology based in-vivo CRO software market segments, market trends and opportunities, and any further data you may need to thrive in the oncology based in-vivo CRO software industry. This oncology based in-vivo CRO software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology-based in-vivo CRO market includes revenues earned by entities by providing preclinical research services such as in-vivo testing via models such as Orthotopic tumor models, tumor passaging, tissue culture models, and others for oncology drugs and devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.